CliffBio
biologic

Ticovac

Tick-Borne Encephalitis Vaccine

Loss of exclusivityAugust 2033projected — 12-year biologic exclusivity estimate
CompanyPfizer Ireland Pharmaceuticals Unlimited Company

Drug detail

Brand nameTicovac
Active ingredientTick-Borne Encephalitis Vaccine
Strength2.4UG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalAugust 2021
Marketing statusRx

More from Pfizer Ireland Pharmaceuticals Unlimited Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ticovac patent cliff — loss of exclusivity August 2033 | CliffBio